Review



mouse anti-abcb6 antibody  (RayBiotech inc)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    RayBiotech inc mouse anti-abcb6 antibody
    Band 3 and <t>ABCB6</t> overexpression in plasma membrane protein of RBCs from patients with DHS and PIEZO1–band 3 colocalization. (A) Left: representative immunoblot of RBC membrane proteins showing band 3 and ABCB6 protein expression normalized to β-actin in the patients DHS1, DHS2, DHS3, DHS4, DHS5, and DHS6 compared with HCs (2 pools of HCs, each of n = 3). Right: densitometric analysis of 3 representative western blotting is shown for band 3 and ABCB6 proteins. Data are presented as mean ± standard deviation; ∗ P < .05; ∗∗ P < .01 (Student t test). (B) Representative confocal imaging by ZEISS LSM 980 Airyscan 2 of HC RBCs treated with vehicle (upper panel) compared with HC RBCs treated with 2.5 μM Yoda1 (10 minutes) (middle panel) and HC RBCs treated with 2.5 μM Yoda1 (20 minutes) (lower panel). Rabbit anti-PIEZO1 antibody is shown in green, mouse anti–band 3 is shown in red. The overlapping of both signals (MERGE) is shown on the right (yellow). (C) Quantification by Pearson correlation of PIEZO1–band 3 colocalization in untreated HC RBCs, HC RBCs + 2.5 μM Yoda1 (10 minutes), and HC RBCs + 2.5 μM Yoda1 (20 minutes) is shown. Data shown are the means of 12 independent acquisitions ± standard error of the mean; P < .05 for trend (ANOVA test), ∗ P < .05 (post hoc correction by Tukey multiple comparisons test).
    Mouse Anti Abcb6 Antibody, supplied by RayBiotech inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mouse anti-abcb6 antibody/product/RayBiotech inc
    Average 90 stars, based on 1 article reviews
    mouse anti-abcb6 antibody - by Bioz Stars, 2026-04
    90/100 stars

    Images

    1) Product Images from "Proteome alterations in erythrocytes with PIEZO1 gain-of-function mutations"

    Article Title: Proteome alterations in erythrocytes with PIEZO1 gain-of-function mutations

    Journal: Blood Advances

    doi: 10.1182/bloodadvances.2022008673

    Band 3 and ABCB6 overexpression in plasma membrane protein of RBCs from patients with DHS and PIEZO1–band 3 colocalization. (A) Left: representative immunoblot of RBC membrane proteins showing band 3 and ABCB6 protein expression normalized to β-actin in the patients DHS1, DHS2, DHS3, DHS4, DHS5, and DHS6 compared with HCs (2 pools of HCs, each of n = 3). Right: densitometric analysis of 3 representative western blotting is shown for band 3 and ABCB6 proteins. Data are presented as mean ± standard deviation; ∗ P < .05; ∗∗ P < .01 (Student t test). (B) Representative confocal imaging by ZEISS LSM 980 Airyscan 2 of HC RBCs treated with vehicle (upper panel) compared with HC RBCs treated with 2.5 μM Yoda1 (10 minutes) (middle panel) and HC RBCs treated with 2.5 μM Yoda1 (20 minutes) (lower panel). Rabbit anti-PIEZO1 antibody is shown in green, mouse anti–band 3 is shown in red. The overlapping of both signals (MERGE) is shown on the right (yellow). (C) Quantification by Pearson correlation of PIEZO1–band 3 colocalization in untreated HC RBCs, HC RBCs + 2.5 μM Yoda1 (10 minutes), and HC RBCs + 2.5 μM Yoda1 (20 minutes) is shown. Data shown are the means of 12 independent acquisitions ± standard error of the mean; P < .05 for trend (ANOVA test), ∗ P < .05 (post hoc correction by Tukey multiple comparisons test).
    Figure Legend Snippet: Band 3 and ABCB6 overexpression in plasma membrane protein of RBCs from patients with DHS and PIEZO1–band 3 colocalization. (A) Left: representative immunoblot of RBC membrane proteins showing band 3 and ABCB6 protein expression normalized to β-actin in the patients DHS1, DHS2, DHS3, DHS4, DHS5, and DHS6 compared with HCs (2 pools of HCs, each of n = 3). Right: densitometric analysis of 3 representative western blotting is shown for band 3 and ABCB6 proteins. Data are presented as mean ± standard deviation; ∗ P < .05; ∗∗ P < .01 (Student t test). (B) Representative confocal imaging by ZEISS LSM 980 Airyscan 2 of HC RBCs treated with vehicle (upper panel) compared with HC RBCs treated with 2.5 μM Yoda1 (10 minutes) (middle panel) and HC RBCs treated with 2.5 μM Yoda1 (20 minutes) (lower panel). Rabbit anti-PIEZO1 antibody is shown in green, mouse anti–band 3 is shown in red. The overlapping of both signals (MERGE) is shown on the right (yellow). (C) Quantification by Pearson correlation of PIEZO1–band 3 colocalization in untreated HC RBCs, HC RBCs + 2.5 μM Yoda1 (10 minutes), and HC RBCs + 2.5 μM Yoda1 (20 minutes) is shown. Data shown are the means of 12 independent acquisitions ± standard error of the mean; P < .05 for trend (ANOVA test), ∗ P < .05 (post hoc correction by Tukey multiple comparisons test).

    Techniques Used: Over Expression, Membrane, Western Blot, Expressing, Standard Deviation, Imaging



    Similar Products

    mouse anti-abcb6 antibody  (RayBiotech inc)
    90
    RayBiotech inc mouse anti-abcb6 antibody
    Band 3 and <t>ABCB6</t> overexpression in plasma membrane protein of RBCs from patients with DHS and PIEZO1–band 3 colocalization. (A) Left: representative immunoblot of RBC membrane proteins showing band 3 and ABCB6 protein expression normalized to β-actin in the patients DHS1, DHS2, DHS3, DHS4, DHS5, and DHS6 compared with HCs (2 pools of HCs, each of n = 3). Right: densitometric analysis of 3 representative western blotting is shown for band 3 and ABCB6 proteins. Data are presented as mean ± standard deviation; ∗ P < .05; ∗∗ P < .01 (Student t test). (B) Representative confocal imaging by ZEISS LSM 980 Airyscan 2 of HC RBCs treated with vehicle (upper panel) compared with HC RBCs treated with 2.5 μM Yoda1 (10 minutes) (middle panel) and HC RBCs treated with 2.5 μM Yoda1 (20 minutes) (lower panel). Rabbit anti-PIEZO1 antibody is shown in green, mouse anti–band 3 is shown in red. The overlapping of both signals (MERGE) is shown on the right (yellow). (C) Quantification by Pearson correlation of PIEZO1–band 3 colocalization in untreated HC RBCs, HC RBCs + 2.5 μM Yoda1 (10 minutes), and HC RBCs + 2.5 μM Yoda1 (20 minutes) is shown. Data shown are the means of 12 independent acquisitions ± standard error of the mean; P < .05 for trend (ANOVA test), ∗ P < .05 (post hoc correction by Tukey multiple comparisons test).
    Mouse Anti Abcb6 Antibody, supplied by RayBiotech inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mouse anti-abcb6 antibody/product/RayBiotech inc
    Average 90 stars, based on 1 article reviews
    mouse anti-abcb6 antibody - by Bioz Stars, 2026-04
    90/100 stars
    		  Buy from Supplier
    anti abcb6 mouse monoclonal  (Santa Cruz Biotechnology)
    93
    Santa Cruz Biotechnology anti abcb6 mouse monoclonal
    Band 3 and <t>ABCB6</t> overexpression in plasma membrane protein of RBCs from patients with DHS and PIEZO1–band 3 colocalization. (A) Left: representative immunoblot of RBC membrane proteins showing band 3 and ABCB6 protein expression normalized to β-actin in the patients DHS1, DHS2, DHS3, DHS4, DHS5, and DHS6 compared with HCs (2 pools of HCs, each of n = 3). Right: densitometric analysis of 3 representative western blotting is shown for band 3 and ABCB6 proteins. Data are presented as mean ± standard deviation; ∗ P < .05; ∗∗ P < .01 (Student t test). (B) Representative confocal imaging by ZEISS LSM 980 Airyscan 2 of HC RBCs treated with vehicle (upper panel) compared with HC RBCs treated with 2.5 μM Yoda1 (10 minutes) (middle panel) and HC RBCs treated with 2.5 μM Yoda1 (20 minutes) (lower panel). Rabbit anti-PIEZO1 antibody is shown in green, mouse anti–band 3 is shown in red. The overlapping of both signals (MERGE) is shown on the right (yellow). (C) Quantification by Pearson correlation of PIEZO1–band 3 colocalization in untreated HC RBCs, HC RBCs + 2.5 μM Yoda1 (10 minutes), and HC RBCs + 2.5 μM Yoda1 (20 minutes) is shown. Data shown are the means of 12 independent acquisitions ± standard error of the mean; P < .05 for trend (ANOVA test), ∗ P < .05 (post hoc correction by Tukey multiple comparisons test).
    Anti Abcb6 Mouse Monoclonal, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti abcb6 mouse monoclonal/product/Santa Cruz Biotechnology
    Average 93 stars, based on 1 article reviews
    anti abcb6 mouse monoclonal - by Bioz Stars, 2026-04
    93/100 stars
    		  Buy from Supplier

    Image Search Results


    Band 3 and ABCB6 overexpression in plasma membrane protein of RBCs from patients with DHS and PIEZO1–band 3 colocalization. (A) Left: representative immunoblot of RBC membrane proteins showing band 3 and ABCB6 protein expression normalized to β-actin in the patients DHS1, DHS2, DHS3, DHS4, DHS5, and DHS6 compared with HCs (2 pools of HCs, each of n = 3). Right: densitometric analysis of 3 representative western blotting is shown for band 3 and ABCB6 proteins. Data are presented as mean ± standard deviation; ∗ P < .05; ∗∗ P < .01 (Student t test). (B) Representative confocal imaging by ZEISS LSM 980 Airyscan 2 of HC RBCs treated with vehicle (upper panel) compared with HC RBCs treated with 2.5 μM Yoda1 (10 minutes) (middle panel) and HC RBCs treated with 2.5 μM Yoda1 (20 minutes) (lower panel). Rabbit anti-PIEZO1 antibody is shown in green, mouse anti–band 3 is shown in red. The overlapping of both signals (MERGE) is shown on the right (yellow). (C) Quantification by Pearson correlation of PIEZO1–band 3 colocalization in untreated HC RBCs, HC RBCs + 2.5 μM Yoda1 (10 minutes), and HC RBCs + 2.5 μM Yoda1 (20 minutes) is shown. Data shown are the means of 12 independent acquisitions ± standard error of the mean; P < .05 for trend (ANOVA test), ∗ P < .05 (post hoc correction by Tukey multiple comparisons test).

    Journal: Blood Advances

    Article Title: Proteome alterations in erythrocytes with PIEZO1 gain-of-function mutations

    doi: 10.1182/bloodadvances.2022008673

    Figure Lengend Snippet: Band 3 and ABCB6 overexpression in plasma membrane protein of RBCs from patients with DHS and PIEZO1–band 3 colocalization. (A) Left: representative immunoblot of RBC membrane proteins showing band 3 and ABCB6 protein expression normalized to β-actin in the patients DHS1, DHS2, DHS3, DHS4, DHS5, and DHS6 compared with HCs (2 pools of HCs, each of n = 3). Right: densitometric analysis of 3 representative western blotting is shown for band 3 and ABCB6 proteins. Data are presented as mean ± standard deviation; ∗ P < .05; ∗∗ P < .01 (Student t test). (B) Representative confocal imaging by ZEISS LSM 980 Airyscan 2 of HC RBCs treated with vehicle (upper panel) compared with HC RBCs treated with 2.5 μM Yoda1 (10 minutes) (middle panel) and HC RBCs treated with 2.5 μM Yoda1 (20 minutes) (lower panel). Rabbit anti-PIEZO1 antibody is shown in green, mouse anti–band 3 is shown in red. The overlapping of both signals (MERGE) is shown on the right (yellow). (C) Quantification by Pearson correlation of PIEZO1–band 3 colocalization in untreated HC RBCs, HC RBCs + 2.5 μM Yoda1 (10 minutes), and HC RBCs + 2.5 μM Yoda1 (20 minutes) is shown. Data shown are the means of 12 independent acquisitions ± standard error of the mean; P < .05 for trend (ANOVA test), ∗ P < .05 (post hoc correction by Tukey multiple comparisons test).

    Article Snippet: Erythrocyte membrane extracts (80 μg protein) were loaded on sodium dodecyl sulfate polyacrylamide gels, transferred onto polyvinylidene difluoride membranes (BioRad, Milan, Italy), and incubated with mouse anti-BAND3 glycoprotein antibody (dilution, 1:5000; GTX11012; GeneTex) and mouse anti-ABCB6 antibody (dilution, 1:1000; 101-10003; Raybiotech, Inc).

    Techniques: Over Expression, Membrane, Western Blot, Expressing, Standard Deviation, Imaging